Efavirenz adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 11: | Line 11: | ||
* [[Rash]] | * [[Rash]] | ||
The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32d6371e-ba56-4294-b732-6d43627c5c47 | publisher = | date = | accessdate = }}</ref> | The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were [[rash]], [[dizziness]], [[nausea]], [[headache]], [[fatigue]], [[insomnia]], and [[vomiting]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32d6371e-ba56-4294-b732-6d43627c5c47 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 06:22, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The most significant adverse reactions observed in patients treated with SUSTIVA are:
- Psychiatric symptoms
- Nervous system symptoms
- Rash
The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.[1]
References
Adapted from the FDA Package Insert.